Can you take Semaglutide and Tirzepatide together?

Read Off Label doesn't make stack recommendations — see the disclaimer. Both compounds have individual mechanism, dose, and risk profiles documented on their respective pages; combining them is a clinical question that depends on the goal, indication, and other context.

Rankings / Comparisons

Semaglutide vs Tirzepatide

Single-agonist GLP-1 vs dual GLP-1/GIP — head-to-head weight loss data and side-effect profile.

Reviewed by Read Off Label · How we grade

Bottom line

On Read Off Label's composite score, Semaglutide and Tirzepatide tie at 6.8/10. The right pick depends on the specific outcome you're optimising for.

Semaglutide

B 6.8/10

aka Ozempic, Wegovy, Rybelsus

Evidence: Strong (8/10)
Benefit: High (8/10)
Risk: Med (GI effects; gallbladder/pancreatitis; altered skin sensation more common at Wegovy HD 7.2 mg) (5/10 safety)
Legality: Rx
Dose: Wegovy (obesity): titrate to 2.4 mg SC weekly; Wegovy HD: 7.2 mg SC weekly in selected adults; Ozempic (T2DM): 0.25-2 mg SC weekly
Class: Prescription
Last reviewed: Jun 8, 2026

Read Off Label grades Semaglutide as B (6.8/10) based on strong evidence, high benefit magnitude, and a med-risk safety profile.

STEP 1: ~15% body weight loss over 68 weeks.

Typical use: Wegovy (obesity): titrate to 2. — Rx.

What it is

STEP 1: ~15% body weight loss over 68 weeks. SELECT 2023: 20% reduction in MACE in obese patients with CVD but no diabetes. FDA approved Wegovy HD 7.2 mg on March 19, 2026 after data showed additional average weight reduction vs lower approved doses with a broadly consistent GLP-1 safety profile; altered skin sensation (sensitivity, pain, burning) was more common at the higher dose and is under further FDA investigation. GI side effects common; rare pancreatitis/gallbladder. Weight regain on cessation. Delayed gastric emptying raises peri-operative aspiration risk — anesthesia guidance now recommends holding GLP-1 agonists before elective surgery. Oral Wegovy (semaglutide tablets) is FDA-approved for chronic weight management; Phase 3 OASIS-4 (n=307, 64 wk): ~13.6% weight loss vs 2.4% placebo (treatment-policy estimand).

Mechanism

GLP-1 receptor agonist: slows gastric emptying; suppresses glucagon; enhances glucose-dependent insulin secretion; central appetite suppression via hypothalamic GLP-1R

Full Semaglutide review →

Tirzepatide

B 6.8/10

aka Mounjaro, Zepbound

Evidence: Strong (8/10)
Benefit: High (most effective approved weight loss drug) (8/10)
Risk: Med (5/10 safety)
Legality: Rx
Dose: Zepbound (obesity): titrate to 10-15 mg SC weekly; Mounjaro (T2DM)
Class: Prescription
Last reviewed: Jun 7, 2026

Read Off Label grades Tirzepatide as B (6.8/10) based on strong evidence, high benefit magnitude, and a med-risk safety profile.

SURMOUNT-1: ~22.

Typical use: Zepbound (obesity): titrate to 10-15 mg SC weekly; Mounjaro (T2DM) — Rx.

What it is

SURMOUNT-1: ~22.5% weight loss over 72 weeks at 15 mg — highest of any approved weight loss drug. SURMOUNT-5 (head-to-head 2025): tirzepatide -20.2% vs semaglutide -13.7% at 72 weeks. SURPASS-CVOT showed CV non-inferiority to dulaglutide. SURMOUNT-1 176-week extension (Heerspink 2026, Diabetes Obes Metab) confirmed sustained weight loss and renal-function preservation. Awaiting SURMOUNT-MMO for CV outcomes in obesity without diabetes.

Mechanism

Dual GIP/GLP-1 receptor agonist; GIP component enhances weight loss and glycemic effects beyond GLP-1 alone; mechanisms similar to semaglutide but more potent

Full Tirzepatide review →

Common questions

Which is better, Semaglutide or Tirzepatide?: On Read Off Label's composite score, Semaglutide and Tirzepatide tie at 6.8/10. The right pick depends on the specific outcome you're optimising for.
What's the difference between Semaglutide and Tirzepatide?: Single-agonist GLP-1 vs dual GLP-1/GIP — head-to-head weight loss data and side-effect profile.
Can you take Semaglutide and Tirzepatide together?: Read Off Label doesn't make stack recommendations — see the disclaimer. Both compounds have individual mechanism, dose, and risk profiles documented on their respective pages; combining them is a clinical question that depends on the goal, indication, and other context.

This is an independent synthesis of published research by a non-clinician. Comparison-page verdicts use the composite Read Off Label score as a tiebreaker, but the right pick for any given person depends on indication, context, and clinician input. See the full disclaimer and methodology.